Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing

Abstract Background Professional society guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) for women with pathogenic variants (PVs) in ovarian cancer-risk genes. Personalization of that intervention is based on gene-specific phenotypes; however, the age of ovarian cancer diagnosis in w...

Full description

Bibliographic Details
Main Authors: Shelly Cummings, Susana San Roman, Jennifer Saam, Ryan Bernhisel, Krystal Brown, Johnathan M. Lancaster, Lydia Usha
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Journal of Ovarian Research
Subjects:
Online Access:https://doi.org/10.1186/s13048-021-00809-w
id doaj-c8345c1edcca47cc9f2904770d06caa4
record_format Article
spelling doaj-c8345c1edcca47cc9f2904770d06caa42021-05-02T11:28:20ZengBMCJournal of Ovarian Research1757-22152021-04-011411710.1186/s13048-021-00809-wAge of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testingShelly Cummings0Susana San Roman1Jennifer Saam2Ryan Bernhisel3Krystal Brown4Johnathan M. Lancaster5Lydia Usha6Myriad Genetics Inc.Myriad Genetics Inc.Myriad Genetics Inc.Myriad Genetics Inc.Myriad Genetics Inc.Myriad Genetics Inc.The Rush Cancer Institute, Rush UniversityAbstract Background Professional society guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) for women with pathogenic variants (PVs) in ovarian cancer-risk genes. Personalization of that intervention is based on gene-specific phenotypes; however, the age of ovarian cancer diagnosis in women with PVs in moderate penetrance ovarian cancer-risk genes is not well characterized. Women who had hereditary cancer panel testing from September 2013–May 2019 were included (N = 631,950). Clinical/demographic information was compared for women with a PV in BRIP1, RAD51C, or RAD51D versus in BRCA1 or BRCA2. Results PVs in BRIP1, RAD51C, or RAD51D were identified in 0.5% of all tested women but in 1.6% of women with a history of ovarian cancer (~ 3-fold increase). PVs in BRCA1 or BRCA2 were identified in 2.4% of all tested women but in 6.1% of women with a history of ovarian cancer (~ 2.5-fold increase). The proportion of women with a personal or family history of ovarian cancer was similar among women with a PV in BRIP1, RAD51C, RAD51D, BRCA1, or BRCA2. The median age at ovarian cancer diagnosis was 53 years for BRCA1, 59 years for BRCA2, 65 years for BRIP1, 62 years for RAD51C, and 57 years for RAD51D. Conclusions These data reinforce the importance of identifying PVs in moderate penetrance ovarian cancer-risk genes. The age at ovarian cancer diagnosis was older for women with PVs in BRIP1, RAD51C, or RAD51D, suggesting that it is safe to delay RRSO until age 45–50 in RAD51D PV carriers and possibly until age 50–55 in BRIP and RAD51C PV carriers.https://doi.org/10.1186/s13048-021-00809-wOvarian cancerPan-cancer panelGenetic testingHereditary ovarian cancer
collection DOAJ
language English
format Article
sources DOAJ
author Shelly Cummings
Susana San Roman
Jennifer Saam
Ryan Bernhisel
Krystal Brown
Johnathan M. Lancaster
Lydia Usha
spellingShingle Shelly Cummings
Susana San Roman
Jennifer Saam
Ryan Bernhisel
Krystal Brown
Johnathan M. Lancaster
Lydia Usha
Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing
Journal of Ovarian Research
Ovarian cancer
Pan-cancer panel
Genetic testing
Hereditary ovarian cancer
author_facet Shelly Cummings
Susana San Roman
Jennifer Saam
Ryan Bernhisel
Krystal Brown
Johnathan M. Lancaster
Lydia Usha
author_sort Shelly Cummings
title Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing
title_short Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing
title_full Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing
title_fullStr Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing
title_full_unstemmed Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing
title_sort age of ovarian cancer diagnosis among brip1, rad51c, and rad51d mutation carriers identified through multi-gene panel testing
publisher BMC
series Journal of Ovarian Research
issn 1757-2215
publishDate 2021-04-01
description Abstract Background Professional society guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) for women with pathogenic variants (PVs) in ovarian cancer-risk genes. Personalization of that intervention is based on gene-specific phenotypes; however, the age of ovarian cancer diagnosis in women with PVs in moderate penetrance ovarian cancer-risk genes is not well characterized. Women who had hereditary cancer panel testing from September 2013–May 2019 were included (N = 631,950). Clinical/demographic information was compared for women with a PV in BRIP1, RAD51C, or RAD51D versus in BRCA1 or BRCA2. Results PVs in BRIP1, RAD51C, or RAD51D were identified in 0.5% of all tested women but in 1.6% of women with a history of ovarian cancer (~ 3-fold increase). PVs in BRCA1 or BRCA2 were identified in 2.4% of all tested women but in 6.1% of women with a history of ovarian cancer (~ 2.5-fold increase). The proportion of women with a personal or family history of ovarian cancer was similar among women with a PV in BRIP1, RAD51C, RAD51D, BRCA1, or BRCA2. The median age at ovarian cancer diagnosis was 53 years for BRCA1, 59 years for BRCA2, 65 years for BRIP1, 62 years for RAD51C, and 57 years for RAD51D. Conclusions These data reinforce the importance of identifying PVs in moderate penetrance ovarian cancer-risk genes. The age at ovarian cancer diagnosis was older for women with PVs in BRIP1, RAD51C, or RAD51D, suggesting that it is safe to delay RRSO until age 45–50 in RAD51D PV carriers and possibly until age 50–55 in BRIP and RAD51C PV carriers.
topic Ovarian cancer
Pan-cancer panel
Genetic testing
Hereditary ovarian cancer
url https://doi.org/10.1186/s13048-021-00809-w
work_keys_str_mv AT shellycummings ageofovariancancerdiagnosisamongbrip1rad51candrad51dmutationcarriersidentifiedthroughmultigenepaneltesting
AT susanasanroman ageofovariancancerdiagnosisamongbrip1rad51candrad51dmutationcarriersidentifiedthroughmultigenepaneltesting
AT jennifersaam ageofovariancancerdiagnosisamongbrip1rad51candrad51dmutationcarriersidentifiedthroughmultigenepaneltesting
AT ryanbernhisel ageofovariancancerdiagnosisamongbrip1rad51candrad51dmutationcarriersidentifiedthroughmultigenepaneltesting
AT krystalbrown ageofovariancancerdiagnosisamongbrip1rad51candrad51dmutationcarriersidentifiedthroughmultigenepaneltesting
AT johnathanmlancaster ageofovariancancerdiagnosisamongbrip1rad51candrad51dmutationcarriersidentifiedthroughmultigenepaneltesting
AT lydiausha ageofovariancancerdiagnosisamongbrip1rad51candrad51dmutationcarriersidentifiedthroughmultigenepaneltesting
_version_ 1721492230962675712